PUBLISHER: Persistence Market Research | PRODUCT CODE: 1513625

PUBLISHER: Persistence Market Research | PRODUCT CODE: 1513625

Stromal Vascular Fraction Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033

PUBLISHED: July 5, 2024

PAGES: 183 Pages

DELIVERY TIME: 2-5 business days

ADD TO COMPARE

SELECT AN OPTION

Description

Persistence Market Research has recently released a comprehensive report on the worldwide market for Stromal Vascular Fraction (SVF). The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure.

Key Insights: Stromal Vascular Fraction Market

Market Size (2024E): USD 96.7 million
Projected Market Value (2033F): USD 136.1 million
Global Market Growth Rate (CAGR 2024 to 2033): 8.2%

Stromal Vascular Fraction Market - Report Scope:

Stromal Vascular Fraction (SVF) plays a crucial role in regenerative medicine due to its high concentration of stem cells and growth factors. SVF is derived from adipose tissue and is used in various therapeutic applications, including wound healing, orthopedic treatments, and cosmetic procedures. The market caters to hospitals, clinics, research institutions, and biotechnology companies, offering a range of SVF preparation devices and kits. Market growth is driven by increasing prevalence of chronic diseases, rising healthcare expenditures, and advancements in SVF technology, enhancing treatment efficacy and patient outcomes.

Market Growth Drivers:

The global Stromal Vascular Fraction market is propelled by several key factors, including growing awareness about regenerative medicine and the therapeutic potential of SVF. The rising incidence of chronic conditions such as osteoarthritis and cardiovascular diseases, coupled with the demand for minimally invasive treatment options, further drives market expansion. Technological advancements, such as the development of automated SVF isolation systems and enhanced cell processing techniques, offer improved treatment outcomes and reduced procedure times, fostering market growth. Moreover, the increasing adoption of SVF-based therapies and the expansion of clinical research create new avenues for market players to reach a wider patient population.

Market Restraints:

Despite promising growth prospects, the Stromal Vascular Fraction market faces challenges related to regulatory compliance, reimbursement policies, and ethical concerns associated with stem cell therapies. Stringent regulations governing the manufacturing, marketing, and use of SVF impose compliance burdens on manufacturers and healthcare providers, affecting market entry barriers and operational costs. Furthermore, limited reimbursement coverage for SVF-based treatments and the high cost of SVF isolation equipment pose challenges for market penetration, particularly in emerging economies with constrained healthcare budgets. Addressing these regulatory and economic barriers requires collaboration between industry stakeholders and policymakers to promote access to safe and affordable SVF solutions.

Market Opportunities:

The Stromal Vascular Fraction market presents significant growth opportunities driven by technological innovations, demographic trends, and evolving healthcare delivery models. The integration of digital health technologies, such as remote monitoring and telemedicine platforms, enhances patient access to SVF therapies and improves treatment adherence and outcomes. Furthermore, the expanding application of SVF beyond traditional therapeutic areas, including in the treatment of autoimmune diseases and neurodegenerative disorders, broadens the market scope and stimulates innovation. Strategic partnerships, investment in research and development, and the introduction of user-friendly, cost-effective SVF solutions are essential to capitalize on emerging opportunities and sustain market leadership in the dynamic regenerative medicine landscape.

Key Questions Answered in the Report:

What are the primary factors driving the growth of the Stromal Vascular Fraction market globally?
Which SVF applications are driving adoption across different healthcare settings?
How are technological advancements reshaping the competitive landscape of the Stromal Vascular Fraction market?
Who are the key players contributing to the Stromal Vascular Fraction market, and what strategies are they employing to maintain market relevance?
What are the emerging trends and future prospects in the global Stromal Vascular Fraction market?

Competitive Intelligence and Business Strategy:

Leading players in the global Stromal Vascular Fraction market, including Cytori Therapeutics Inc., IntelliCell BioSciences Inc., and LifeCell Corporation, focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop advanced SVF solutions, including automated isolation systems and all-in-one processing kits, catering to diverse patient needs and clinical requirements. Collaborations with healthcare providers, research institutions, and regulatory agencies facilitate market access and promote technology adoption. Moreover, emphasis on clinical research, evidence-based practice, and patient education fosters market growth and enhances patient outcomes in the rapidly evolving regenerative medicine landscape.

Key Companies Profiled:

Cytori Therapeutics Inc.
IntelliCell BioSciences Inc.
Cellular Biomedicines Group, Inc.
GE Healthcare (Biosafe Group SA)
Lifecell Corporation (Allergen PLC)
Tissue Genesis Inc.
InGeneron, Inc.
Human med AG
MEDICAN CO., LTD
Hairline International
Genesis Biosystems, Inc.
iXCells Biotechnologies USA, LLC
Kyocera Corporation
Medikan International Inc.

Key Segments Covered in Manufacturing of Industry Research

Product:

SVF Aspiration Products
SVF Transfer Products
SVF Isolation Products

Application:

Cosmetic Applications
Orthopedic Applications
Soft Tissue Applications

End User:

Hospitals
Specialty Clinics
Stem Cell Banks/Laboratories

Region:

North America
Latin America
Europe
South Asia
East Asia

Product Code: PMRREP20914

1. Executive Summary

1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage/Taxonomy
2.2. Market Definition/Scope/Limitations
2.3. Inclusion And Exclusions

3. Key Market Trends

3.1. Key Trends Impacting the Market
3.2. Development/Innovation Trends

4. Key Success Factors

4.1. Product Adoption / Usage Analysis
4.2. New Product Launches
4.3. Technology Roadmap
4.4. PESTEL Analysis
4.5. Porter's Analysis
4.6. Product Features/ USPs
4.7. Key Promotional Strategies, By Key Manufacturers
4.8. Regulatory Landscape

5. Market Background

5.1. Macro-Economic Factors
- 5.1.1. Global GDP Growth Outlook
- 5.1.2. Global Healthcare Industry Outlook
- 5.1.3. Global Adipose-Derived Stem Cell Market Overview
5.2. Forecast Factors - Relevance & Impact
- 5.2.1. Key Player's Historic Growth
- 5.2.2. Market Consolidation Activities
- 5.2.3. New Product Launches / Approvals
- 5.2.4. Rising Demand of Stromal Vascular Fraction
- 5.2.5. Increasing Incidence of Skeletal Muscular Disorder
- 5.2.6. Increasing Research & Development Activities
5.3. Market Dynamics
- 5.3.1. Drivers
- 5.3.2. Restraints
- 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

6.1. COVID-19 and Impact Analysis
- 6.1.1. By Product
- 6.1.2. By Application
- 6.1.3. By End User
- 6.1.4. By Region
6.2. 2024 Market Scenario

7. Global Stromal Vascular Fraction Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2033

7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2033
- 7.2.1. Y-o-Y Growth Trend Analysis
- 7.2.2. Absolute $ Opportunity Analysis

8. Global Stromal Vascular Fraction Market Analysis 2019-2023 and Forecast 2024-2033, By Product

8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis, By Product, 2019-2023
8.3. Current and Future Market Size (US$ Mn) Analysis Forecast, By Product, 2024-2033
- 8.3.1. SVF Aspiration Products
- 8.3.2. SVF Transfer Products
- 8.3.3. SVF Isolation Products
  - 8.3.3.1. Enzymatic Isolation Products
  - 8.3.3.2. Non-enzymatic Isolation Products
  - 8.3.3.3. Automated POC Devices
8.4. Market Attractiveness Analysis By Product

9. Global Stromal Vascular Fraction Market Analysis 2019-2023 and Forecast 2024-2033, By Application

9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis, By Application, 2019-2023
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Application, 2024-2033
- 9.3.1. Cosmetic Applications
- 9.3.2. Orthopedic Applications
- 9.3.3. Soft Tissue Applications
- 9.3.4. Others
9.4. Market Attractiveness Analysis By Application

10. Global Stromal Vascular Fraction Market Analysis 2019-2023 and Forecast 2024-2033, By End User

10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis, By End User, 2019-2023
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2033
- 10.3.1. Hospitals
- 10.3.2. Specialty Clinics
- 10.3.3. Stem Cell Banks/Laboratories
- 10.3.4. Others
10.4. Market Attractiveness Analysis By End User

11. Global Stromal Vascular Fraction Market Analysis 2019-2023 and Forecast 2024-2033, By Region

11.1. Introduction
11.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2023
11.3. Current and Future Market Size (US$ Mn) Analysis Forecast, By Region, 2024-2033
- 11.3.1. North America
- 11.3.2. Latin America
- 11.3.3. Europe
- 11.3.4. East Asia
- 11.3.5. South Asia
- 11.3.6. Oceania
- 11.3.7. Middle East and Africa
11.4. Market Attractiveness Analysis By Region

12. North America Stromal Vascular Fraction Market Analysis 2019-2023 and Forecast 2024-2033

12.1. Introduction
12.2. Historical Market Size (US$ Mn) Trend Analysis, By Market Taxonomy, 2019-2023
12.3. Current and Future Market Size (US$ Mn) and Forecast, By Market Taxonomy, 2024-2033
- 12.3.1. By Country
  - 12.3.1.1. U.S.
  - 12.3.1.2. Canada
- 12.3.2. By Product
- 12.3.3. By Application
- 12.3.4. By End User
12.4. Market Attractiveness Analysis
- 12.4.1. By Country
- 12.4.2. By Product
- 12.4.3. By Application
- 12.4.4. By End User
12.5. Key Market Participants - Intensity Mapping
12.6. Drivers and Restraints - Impact Analysis
12.7. Key Market Trends
12.8. Country Level Analysis & Forecast
- 12.8.1. U.S. Stromal Vascular Fraction Market
  - 12.8.1.1. Introduction
  - 12.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 12.8.1.2.1. By Product
    - 12.8.1.2.2. By Application
    - 12.8.1.2.3. By End User
- 12.8.2. Canada Stromal Vascular Fraction Market
  - 12.8.2.1. Introduction
  - 12.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 12.8.2.2.1. By Product
    - 12.8.2.2.2. By Application
    - 12.8.2.2.3. By End User

13. Latin America Stromal Vascular Fraction Market Analysis 2019-2023 and Forecast 2024-2033

13.1. Introduction
13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
13.3. Current and Future Market Size (US$ Mn) Analysis & Forecast By Market Taxonomy, 2024-2033
- 13.3.1. By Country
  - 13.3.1.1. Brazil
  - 13.3.1.2. Argentina
  - 13.3.1.3. Mexico
  - 13.3.1.4. Rest of Latin America
- 13.3.2. By Product
- 13.3.3. By Application
- 13.3.4. By End User
13.4. Market Attractiveness Analysis
- 13.4.1. By Country
- 13.4.2. By Product
- 13.4.3. By Application
- 13.4.4. By End User
13.5. Key Market Participants - Intensity Mapping
13.6. Drivers and Restraints - Impact Analysis
13.7. Key Market Trends
13.8. Country Level Analysis & Forecast
- 13.8.1. Brazil Stromal Vascular Fraction Market
  - 13.8.1.1. Introduction
  - 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.1.2.1. By Product
    - 13.8.1.2.2. By Application
    - 13.8.1.2.3. By End User
- 13.8.2. Argentina Stromal Vascular Fraction Market
  - 13.8.2.1. Introduction
  - 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.2.2.1. By Product
    - 13.8.2.2.2. By Application
    - 13.8.2.2.3. By End User
- 13.8.3. Mexico Stromal Vascular Fraction Market
  - 13.8.3.1. Introduction
  - 13.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.3.2.1. By Product
    - 13.8.3.2.2. By Application
    - 13.8.3.2.3. By End User

14. Europe Stromal Vascular Fraction Market Analysis 2019-2023 and Forecast 2024-2033

14.1. Introduction
14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2033
- 14.3.1. By Country
  - 14.3.1.1. Germany
  - 14.3.1.2. Italy
  - 14.3.1.3. France
  - 14.3.1.4. U.K.
  - 14.3.1.5. Spain
  - 14.3.1.6. BENELUX
  - 14.3.1.7. Nordic Countries
  - 14.3.1.8. Russia
  - 14.3.1.9. Rest of Europe
- 14.3.2. By Product
- 14.3.3. By Application
- 14.3.4. By End User
14.4. Market Attractiveness Analysis
- 14.4.1. By Country
- 14.4.2. By Product
- 14.4.3. By Application
- 14.4.4. By End User
14.5. Key Market Participants - Intensity Mapping
14.6. Drivers and Restraints - Impact Analysis
14.7. Key Market Trends
14.8. Country Level Analysis & Forecast
- 14.8.1. Germany Stromal Vascular Fraction Market
  - 14.8.1.1. Introduction
  - 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.1.2.1. By Product
    - 14.8.1.2.2. By Application
    - 14.8.1.2.3. By End User
- 14.8.2. France Stromal Vascular Fraction Market
  - 14.8.2.1. Introduction
  - 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.2.2.1. By Product
    - 14.8.2.2.2. By Application
    - 14.8.2.2.3. By End User
- 14.8.3. Italy Stromal Vascular Fraction Market
  - 14.8.3.1. Introduction
  - 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.3.2.1. By Product
    - 14.8.3.2.2. By Application
    - 14.8.3.2.3. By End User
- 14.8.4. Spain Stromal Vascular Fraction Market
  - 14.8.4.1. Introduction
  - 14.8.4.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.4.2.1. By Product
    - 14.8.4.2.2. By Application
    - 14.8.4.2.3. By End User
- 14.8.5. U.K. Stromal Vascular Fraction Market
  - 14.8.5.1. Introduction
  - 14.8.5.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.5.2.1. By Product
    - 14.8.5.2.2. By Application
    - 14.8.5.2.3. By End User
- 14.8.6. BENULUX Stromal Vascular Fraction Market
  - 14.8.6.1. Introduction
  - 14.8.6.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.6.2.1. By Product
    - 14.8.6.2.2. By Application
    - 14.8.6.2.3. By End User
- 14.8.7. Nordic Countries Stromal Vascular Fraction Market
  - 14.8.7.1. Introduction
  - 14.8.7.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.7.2.1. By Product
    - 14.8.7.2.2. By Application
    - 14.8.7.2.3. By End User
- 14.8.8. Russia Stromal Vascular Fraction Market
  - 14.8.8.1. Introduction
  - 14.8.8.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.8.2.1. By Product
    - 14.8.8.2.2. By Application
    - 14.8.8.2.3. By End User

15. South Asia Stromal Vascular Fraction Market Analysis 2019-2023 and Forecast 2024-2033

15.1. Introduction
15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2033
- 15.3.1. By Country
  - 15.3.1.1. India
  - 15.3.1.2. Thailand
  - 15.3.1.3. Indonesia
  - 15.3.1.4. Malaysia
  - 15.3.1.5. Philippines
  - 15.3.1.6. Rest of South Asia
- 15.3.2. By Product
- 15.3.3. By Application
- 15.3.4. By End User
15.4. Market Attractiveness Analysis
- 15.4.1. By Country
- 15.4.2. By Product
- 15.4.3. By Application
- 15.4.4. By End User
15.5. Key Market Participants - Intensity Mapping
15.6. Drivers and Restraints - Impact Analysis
15.7. Key Market Trends
15.8. Country Level Analysis & Forecast
- 15.8.1. India Stromal Vascular Fraction Market
  - 15.8.1.1. Introduction
  - 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.1.2.1. By Product
    - 15.8.1.2.2. By Application
    - 15.8.1.2.3. By End User
- 15.8.2. Indonesia Stromal Vascular Fraction Market
  - 15.8.2.1. Introduction
  - 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.2.2.1. By Product
    - 15.8.2.2.2. By Application
    - 15.8.2.2.3. By End User
- 15.8.3. Malaysia Stromal Vascular Fraction Market
  - 15.8.3.1. Introduction
  - 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.3.2.1. By Product
    - 15.8.3.2.2. By Application
    - 15.8.3.2.3. By End User
- 15.8.4. Philippines Stromal Vascular Fraction Market
  - 15.8.4.1. Introduction
  - 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.4.2.1. By Product
    - 15.8.4.2.2. By Application
    - 15.8.4.2.3. By End User
- 15.8.5. Thailand Stromal Vascular Fraction Market
  - 15.8.5.1. Introduction
  - 15.8.5.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.5.2.1. By Product
    - 15.8.5.2.2. By Application
    - 15.8.5.2.3. By End User

16. East Asia Stromal Vascular Fraction Market Analysis 2019-2023 and Forecast 2024-2033

16.1. Introduction
16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2033
- 16.3.1. By Country
  - 16.3.1.1. China
  - 16.3.1.2. Japan
  - 16.3.1.3. South Korea
- 16.3.2. By Product
- 16.3.3. By Application
- 16.3.4. By End User
16.4. Market Attractiveness Analysis
- 16.4.1. By Country
- 16.4.2. By Product
- 16.4.3. By Application
- 16.4.4. By End User
16.5. Key Market Participants - Intensity Mapping
16.6. Drivers and Restraints - Impact Analysis
16.7. Key Market Trends
16.8. Country Level Analysis & Forecast
- 16.8.1. China Stromal Vascular Fraction Market
  - 16.8.1.1. Introduction
  - 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 16.8.1.2.1. By Product
    - 16.8.1.2.2. By Application
    - 16.8.1.2.3. By End User
- 16.8.2. Japan Stromal Vascular Fraction Market
  - 16.8.2.1. Introduction
  - 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 16.8.2.2.1. By Product
    - 16.8.2.2.2. By Application
    - 16.8.2.2.3. By End User
- 16.8.3. South Korea Stromal Vascular Fraction Market
  - 16.8.3.1. Introduction
  - 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 16.8.3.2.1. By Product
    - 16.8.3.2.2. By Application
    - 16.8.3.2.3. By End User

17. Oceania Stromal Vascular Fraction Market Analysis 2019-2023 and Forecast 2024-2033

17.1. Introduction
17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2033
- 17.3.1. By Country
  - 17.3.1.1. Australia
  - 17.3.1.2. New Zealand
- 17.3.2. By Product
- 17.3.3. By Application
- 17.3.4. By End User
17.4. Market Attractiveness Analysis
- 17.4.1. By Country
- 17.4.2. By Product
- 17.4.3. By Application
- 17.4.4. By End User
17.5. Key Market Participants - Intensity Mapping
17.6. Drivers and Restraints - Impact Analysis
17.7. Key Market Trends
17.8. Country Level Analysis & Forecast
- 17.8.1. Australia Stromal Vascular Fraction Market
  - 17.8.1.1. Introduction
  - 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 17.8.1.2.1. By Product
    - 17.8.1.2.2. By Application
    - 17.8.1.2.3. By End User
- 17.8.2. New Zealand Stromal Vascular Fraction Market
  - 17.8.2.1. Introduction
  - 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 17.8.2.2.1. By Product
    - 17.8.2.2.2. By Application
    - 17.8.2.2.3. By End User

18. Middle East and Africa (MEA) Stromal Vascular Fraction Market Analysis 2019-2023 and Forecast 2024-2033

18.1. Introduction
18.2. Historical Market Size (US$ Mn Trend Analysis By Market Taxonomy, 2019-2023
18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2033
- 18.3.1. By Country
  - 18.3.1.1. GCC Countries
  - 18.3.1.2. Turkey
  - 18.3.1.3. Egypt
  - 18.3.1.4. North Africa
  - 18.3.1.5. South Africa
  - 18.3.1.6. Rest of Middle East and Africa
- 18.3.2. By Product
- 18.3.3. By Application
- 18.3.4. By End User
18.4. Market Attractiveness Analysis
- 18.4.1. By Country
- 18.4.2. By Product
- 18.4.3. By Application
- 18.4.4. By End User
18.5. Key Market Participants - Intensity Mapping
18.6. Drivers and Restraints - Impact Analysis
18.7. Key Market Trends
18.8. Country Level Analysis & Forecast
- 18.8.1. GCC Countries Stromal Vascular Fraction Market
  - 18.8.1.1. Introduction
  - 18.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 18.8.1.2.1. By Product
    - 18.8.1.2.2. By Application
    - 18.8.1.2.3. By End User
- 18.8.2. Turkey Stromal Vascular Fraction Market
  - 18.8.2.1. Introduction
  - 18.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 18.8.2.2.1. By Product
    - 18.8.2.2.2. By Application
    - 18.8.2.2.3. By End User
- 18.8.3. Egypt Stromal Vascular Fraction Market
  - 18.8.3.1. Introduction
  - 18.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 18.8.3.2.1. By Product
    - 18.8.3.2.2. By Application
    - 18.8.3.2.3. By End User
- 18.8.4. South Africa Stromal Vascular Fraction Market
  - 18.8.4.1. Introduction
  - 18.8.4.2. Market Analysis and Forecast by Market Taxonomy
    - 18.8.4.2.1. By Product
    - 18.8.4.2.2. By Application
    - 18.8.4.2.3. By End User
- 18.8.5. North Africa Stromal Vascular Fraction Market
  - 18.8.5.1. Introduction
  - 18.8.5.2. Market Analysis and Forecast by Market Taxonomy
    - 18.8.5.2.1. By Product
    - 18.8.5.2.2. By Application
    - 18.8.5.2.3. By End User

19. Market Structure Analysis

19.1. Market Analysis by Tier of Companies
19.2. Market Share Analysis of Top Players
19.3. Market Presence Analysis
- 19.3.1. By Regional Footprint of Players
- 19.3.2. By Product Footprint of Players
- 19.3.3. By Channel Footprint of Players

20. Competition Analysis

20.1. Competition Dashboard
20.2. Competition Benchmarking
20.3. Competition Deep Dive
- 20.3.1. Cytori Therapeutics Inc
  - 20.3.1.1. Company Overview
  - 20.3.1.2. Product Portfolio
  - 20.3.1.3. Sales Footprint
  - 20.3.1.4. Key Financials
  - 20.3.1.5. SWOT Analysis
  - 20.3.1.6. Key Developments
  - 20.3.1.7. Strategy Overview
    - 20.3.1.7.1. Marketing Strategy
    - 20.3.1.7.2. Product Strategy
    - 20.3.1.7.3. Channel Strategy
- 20.3.2. IntelliCell BioSciences Inc.
  - 20.3.2.1. Company Overview
  - 20.3.2.2. Product Portfolio
  - 20.3.2.3. Sales Footprint
  - 20.3.2.4. Key Financials
  - 20.3.2.5. SWOT Analysis
  - 20.3.2.6. Key Developments
  - 20.3.2.7. Strategy Overview
    - 20.3.2.7.1. Marketing Strategy
    - 20.3.2.7.2. Product Strategy
    - 20.3.2.7.3. Channel Strategy
- 20.3.3. Cellular Biomedicines Group, Inc.
  - 20.3.3.1. Company Overview
  - 20.3.3.2. Product Portfolio
  - 20.3.3.3. Sales Footprint
  - 20.3.3.4. Key Financials
  - 20.3.3.5. SWOT Analysis
  - 20.3.3.6. Key Developments
  - 20.3.3.7. Strategy Overview
    - 20.3.3.7.1. Marketing Strategy
    - 20.3.3.7.2. Product Strategy
    - 20.3.3.7.3. Channel Strategy
- 20.3.4. GE Healthcare (Biosafe Group SA)
  - 20.3.4.1. Company Overview
  - 20.3.4.2. Product Portfolio
  - 20.3.4.3. Sales Footprint
  - 20.3.4.4. Key Financials
  - 20.3.4.5. SWOT Analysis
  - 20.3.4.6. Key Developments
  - 20.3.4.7. Strategy Overview
    - 20.3.4.7.1. Marketing Strategy
    - 20.3.4.7.2. Product Strategy
    - 20.3.4.7.3. Channel Strategy
- 20.3.5. Lifecell Corporation (Allergen PLC)
  - 20.3.5.1. Company Overview
  - 20.3.5.2. Product Portfolio
  - 20.3.5.3. Sales Footprint
  - 20.3.5.4. Key Financials
  - 20.3.5.5. SWOT Analysis
  - 20.3.5.6. Key Developments
  - 20.3.5.7. Strategy Overview
    - 20.3.5.7.1. Marketing Strategy
    - 20.3.5.7.2. Product Strategy
    - 20.3.5.7.3. Channel Strategy
- 20.3.6. Tissue Genesis Inc.
  - 20.3.6.1. Company Overview
  - 20.3.6.2. Product Portfolio
  - 20.3.6.3. Sales Footprint
  - 20.3.6.4. Key Financials
  - 20.3.6.5. SWOT Analysis
  - 20.3.6.6. Key Developments
  - 20.3.6.7. Strategy Overview
    - 20.3.6.7.1. Marketing Strategy
    - 20.3.6.7.2. Product Strategy
    - 20.3.6.7.3. Channel Strategy
- 20.3.7. InGeneron, Inc.
  - 20.3.7.1. Company Overview
  - 20.3.7.2. Product Portfolio
  - 20.3.7.3. Sales Footprint
  - 20.3.7.4. Key Financials
  - 20.3.7.5. SWOT Analysis
  - 20.3.7.6. Key Developments
  - 20.3.7.7. Strategy Overview
    - 20.3.7.7.1. Marketing Strategy
    - 20.3.7.7.2. Product Strategy
    - 20.3.7.7.3. Channel Strategy
- 20.3.8. Human med AG
  - 20.3.8.1. Company Overview
  - 20.3.8.2. Product Portfolio
  - 20.3.8.3. Sales Footprint
  - 20.3.8.4. Key Financials
  - 20.3.8.5. SWOT Analysis
  - 20.3.8.6. Key Developments
  - 20.3.8.7. Strategy Overview
    - 20.3.8.7.1. Marketing Strategy
    - 20.3.8.7.2. Product Strategy
    - 20.3.8.7.3. Channel Strategy
- 20.3.9. MEDICAN CO., LTD
  - 20.3.9.1. Company Overview
  - 20.3.9.2. Product Portfolio
  - 20.3.9.3. Sales Footprint
  - 20.3.9.4. Key Financials
  - 20.3.9.5. SWOT Analysis
  - 20.3.9.6. Key Developments
  - 20.3.9.7. Strategy Overview
    - 20.3.9.7.1. Marketing Strategy
    - 20.3.9.7.2. Product Strategy
    - 20.3.9.7.3. Channel Strategy
- 20.3.10. Hairline International
  - 20.3.10.1. Company Overview
  - 20.3.10.2. Product Portfolio
  - 20.3.10.3. Sales Footprint
  - 20.3.10.4. Key Financials
  - 20.3.10.5. SWOT Analysis
  - 20.3.10.6. Key Developments
  - 20.3.10.7. Strategy Overview
    - 20.3.10.7.1. Marketing Strategy
    - 20.3.10.7.2. Product Strategy
    - 20.3.10.7.3. Channel Strategy
- 20.3.11. Genesis Biosystems, Inc
  - 20.3.11.1. Company Overview
  - 20.3.11.2. Product Portfolio
  - 20.3.11.3. Sales Footprint
  - 20.3.11.4. Key Financials
  - 20.3.11.5. SWOT Analysis
  - 20.3.11.6. Key Developments
  - 20.3.11.7. Strategy Overview
    - 20.3.11.7.1. Marketing Strategy
    - 20.3.11.7.2. Product Strategy
    - 20.3.11.7.3. Channel Strategy
- 20.3.12. iXCells Biotechnologies USA, LLC
  - 20.3.12.1. Company Overview
  - 20.3.12.2. Product Portfolio
  - 20.3.12.3. Sales Footprint
  - 20.3.12.4. Key Financials
  - 20.3.12.5. SWOT Analysis
  - 20.3.12.6. Key Developments
  - 20.3.12.7. Strategy Overview
    - 20.3.12.7.1. Marketing Strategy
    - 20.3.12.7.2. Product Strategy
    - 20.3.12.7.3. Channel Strategy
- 20.3.13. Kyocera Corporation
  - 20.3.13.1. Company Overview
  - 20.3.13.2. Product Portfolio
  - 20.3.13.3. Sales Footprint
  - 20.3.13.4. Key Financials
  - 20.3.13.5. SWOT Analysis
  - 20.3.13.6. Key Developments
  - 20.3.13.7. Strategy Overview
    - 20.3.13.7.1. Marketing Strategy
    - 20.3.13.7.2. Product Strategy
    - 20.3.13.7.3. Channel Strategy
- 20.3.14. Medikan International Inc
  - 20.3.14.1. Company Overview
  - 20.3.14.2. Product Portfolio
  - 20.3.14.3. Sales Footprint
  - 20.3.14.4. Key Financials
  - 20.3.14.5. SWOT Analysis
  - 20.3.14.6. Key Developments
  - 20.3.14.7. Strategy Overview
    - 20.3.14.7.1. Marketing Strategy
    - 20.3.14.7.2. Product Strategy
    - 20.3.14.7.3. Channel Strategy

21. Assumptions and Acronyms Used

22. Research Methodology

Have a question?

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Christine Sirois

Manager - Americas

+1-860-674-8796

SEE OUR FAQ